LEADING EDGE BIO

Sam Altman’s investments in Retro Biosciences and other "hard" startups signify a strategic shift towards addressing some of humanity’s most profound challenges. By focusing on long-term, high-impact goals, Altman is not just betting on financial returns but on the future of human advancement. As Retro Biosciences continues its quest to extend human life, it embodies the spirit of innovation and ambition that could reshape the biotech landscape for years to come.

As gene therapies move from rare diseases into larger therapeutic areas, understanding their nomenclature becomes increasingly valuable for scientists, clinicians, investors, business development professionals, and anyone navigating modern biotechnology.

Why Mitochondrial Gene Editing May Become the Next Platform Technology in Genetic Medicine One of the most interesting trends in biotechnology is that entirely new companies are increasingly being built around a single enabling platform rather than a single therapeutic asset. The recent launch of Primera Therapeutics is an excellent example. While headlines focused on the company's strategic collaboration with Cellectis and a partnership valued at up to $750 million, the more

Why One-Time Gene Therapies Are Redefining the Business of Medicine For decades, the pharmaceutical industry has operated under a remarkably consistent economic model. Develop a medicine. Treat patients over many years. Generate recurring clinical benefit and recurring revenue. That model is beginning to change. Gene therapies are introducing an entirely new economic framework, one in which a single treatment has the potential to provide years, or perhaps decades, of clinical

AI Is Becoming Biopharma's Operating System: Why the Future of Drug Discovery Is About More Than Algorithms Over the past several years, biotechnology has experienced one of the fastest technological shifts in its history. Artificial intelligence has moved from an interesting research tool to an increasingly essential component of how modern medicines are discovered, developed, and commercialized. The conversation has changed remarkably quickly. Only a few years ago, AI compa

Why Pharmaceutical Companies Are Investing Earlier Than Ever There was a time when pharmaceutical companies primarily acquired innovation. Today, they increasingly invest in it long before it reaches the market. That shift represents far more than a change in financing strategy. It reflects a fundamental transformation in how innovation itself is created. Over the past decade, nearly every major biopharmaceutical company has expanded its presence in venture investing, corpora

What the Universal Flu Vaccine Reveals About the Evolution of mRNA Medicine Scientific breakthroughs rarely arrive overnight. From the outside, it can appear as though a technology suddenly transforms medicine. Those of us fortunate enough to work behind the scenes know a different story. Breakthroughs are often the culmination of decades of incremental scientific advances, failed experiments, manufacturing innovations, regulatory learning, and countless collaborations that q

What FDA Approvals Really Tell Us About the State of Biopharmaceutical Innovation The FDA approved 37 novel medicines in 2022, a figure that sits modestly above the historical average. On the surface, it is an encouraging statistic. Beneath the headline, however, it tells a much more interesting story. Given the disruption caused by the COVID-19 pandemic, this level of productivity was far from inevitable. Clinical trial recruitment slowed dramatically during 2020 and 2021. H

In biotechnology, the next decade won't belong to companies with the largest datasets or the fastest algorithms. It will belong to those that know how to fold science, artificial intelligence, human expertise, and strategic partnerships into platforms that consistently reduce uncertainty and accelerate innovation. Those are the platforms that will shape the future of medicine.